- • Sven Abend has decided to resign from Lonza to take a CEO position in Germany.
- • Recruitment plans are under way to appoint a permanent replacement.
- • LSI is performing well and the segment carve-out process is nearing completion.
Sven Abend has decided to resign from his position as a member of the Executive Committee of Lonza Group. He will relocate to Germany, where he has accepted the role of CEO.
Sven joined Lonza Group in 2014 as Chief Strategy Officer. He has held the position of Chief Operating Officer and Head of Lonza Specialty Ingredients (LSI) since 2016. He will complete a full handover of his key responsibilities before his departure.
Albert M. Baehny commented, “We thank Sven for his contribution to Lonza Specialty Ingredients (LSI). In recent years, he has redesigned the segment to bring greater clarity to our offer while enhancing operational efficiency. He has also overseen the execution of the carve-out of LSI from the Lonza Group business.”
“In recent months, the LSI segment has played a critical role in controlling the spread of COVID-19 (coronavirus), by meeting an increased level of interest and demand for microbial control and disinfection solutions. In this context, the segment is performing well and we are drawing close to the completion of the segment carve-out process.”
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.
Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.
Lonza Group Ltd.
Münchensteinerstraße 38
CH4002 Basel
Telefon: +41 (61) 3168638
Telefax: +41 (61) 3169638
http://www.lonza.com
Telefon: +41 (61) 316-8540
Fax: +41 (61) 316-9540
E-Mail: dirk.oehlers@lonza.com
Head Public Relations
Telefon: +41 (61) 316-8929
E-Mail: sanna.fowler@lonza.com
